Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Tamta Makharadze"'
Autor:
Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Ana Baramidze, Davit Giorgadze, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Siyu Li, Yuntong Li, Manika Kaul, Ruben G.W. Quek, Jean-Francois Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel
Publikováno v:
Journal of Thoracic Oncology. 18:755-768
Autor:
Claire Verschraegen, Zoran Andric, Fedor Moiseenko, Tamta Makharadze, Sergii Shevnya, Alona Oleksiienko, Eduardo Yañez Ruiz, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Sijin Park, Hana Ju, Yuichiro Ohe
Publikováno v:
BioDrugs. 36:749-760
CT-P16 is a candidate bevacizumab biosimilar.This double-blind, multicenter, parallel-group, phase III study aimed to establish equivalent efficacy between CT-P16 and European Union-approved reference bevacizumab (EU-bevacizumab) in patients with met
Autor:
Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner, Brizio Moreno-Jaime, Rodolfo Passalacqua, Siyu Li, Kristina McGuire, Manika Kaul, Anne Paccaly, Ruben G. W. Quek, Bo Gao, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Giuseppe Gullo, Petra Rietschel
Publikováno v:
Nature Medicine. 28:2374-2380
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer
Autor:
Tamta Makharadze, Ruben G. W. Quek, Tamar Melkadze, Miranda Gogishvili, Cristina Ivanescu, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner, Brizio Moreno‐Jaime, Rodolfo Passalacqua, Gerasimos Konidaris, Petra Rietschel, Giuseppe Gullo
Publikováno v:
Cancer.
Autor:
Ying, Cheng, Liang, Han, Lin, Wu, Jun, Chen, Hongmei, Sun, Guilan, Wen, Yinghua, Ji, Mikhail, Dvorkin, Jianhua, Shi, Zhijie, Pan, Jinsheng, Shi, Xicheng, Wang, Yuansong, Bai, Tamar, Melkadze, Yueyin, Pan, Xuhong, Min, Maksym, Viguro, Xingya, Li, Yanqiu, Zhao, Junquan, Yang, Tamta, Makharadze, Ekaterine, Arkania, Wenying, Kang, Qingyu, Wang, Jun, Zhu, Denys, Pominchuk
Publikováno v:
JAMA. 328(12)
Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients with extensive-stage small cell lung cancer (SCLC). It remained unknown whether adding a programmed cell death 1 (PD-1)
Autor:
Nuran Katgi, Z. Andric, Elena Poddubskaya, Rita de Cassia Costamilan, Chaiyut Charoentum, Eduardo P Yañez Ruiz, Tamta Makharadze, Andrea Fulop, Susana Millan, D. Trukhin, Ana Del Campo García, Ravi Shankar Bellala, Yamil Alonso Lopez Chuken, Kostas N. Syrigos, Alexandra Paravisini, Amalia Florez, Jasmin Reyes-Igama, Irfhan Ali Hyder Ali, Stella Investigators, Ilieva Rumyana
Publikováno v:
Biodrugs
Background MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin®; EU-bevacizumab). Objectives To confirm clinical similarity between MB02 and EU-bevacizumab, a comparab
Autor:
Frank Seebach, Naiyer A. Rizvi, Semra Paydas, Chieh I. Chen, Ahmet Sezer, Mustafa Ozguroglu, Oleg Gladkov, George D. Yancopoulos, Irfan Cicin, David M. Weinreich, Israel Lowy, Mahmut Gumus, Virote Sriuranpong, P. Rietschel, Kristina McGuire, Dmitry Bentsion, Marina Nechaeva, Saadettin Kilickap, Miranda Gogishvili, Bo Gao, Siyu Li, Igor Bondarenko, S. Lee, Giuseppe Gullo, Haci Mehmet Turk, Philip Clingan, Tamta Makharadze
Publikováno v:
The Lancet. 397:592-604
We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.In EMPOWER-Lung 1, a multicentre, open-label, global,
Autor:
Robin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, Ahmed Kaseb, Shukui Qin, Andrew X Zhu, Stephen L Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Kamalika Banerjee, Saswati Hazra, Jonathan Fawcett, Thomas Yau
Publikováno v:
The Lancet. Oncology. 23(8)
Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma.
Autor:
Martin J. Edelman, Mikhail Dvorkin, Konstatin Laktionov, Alejandro Navarro, Oscar Juan-Vidal, Vadim Kozlov, Gil Golden, Odette Jordan, CQ Deng, Dmitriy Bentsion, Christos Chouaid, Hristo Dechev, Afshin Dowlati, Natalia Fernández Núñez, Olexandr Ivashchuk, Ivane Kiladze, Tsira Kortua, Natasha Leighl, Aleksandr Luft, Tamta Makharadze, YoungJoo Min, Xavier Quantin
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 166
Topotecan is approved as second-line treatment for small cell lung cancer (SCLC). Irinotecan is also frequently used given its more convenient schedule and superior tolerability. Preclinical studies support disialoganglioside (GD2) as an SCLC target
Autor:
Ralph V. Boccia, David H. Henry, Tamta Makharadze, Nicole Blackman, Jeffrey A. Gilreath, Anna Krupa
Publikováno v:
American journal of hematology. 96(12)
Erythropoiesis-stimulating agents (ESA) are effective for chemotherapy-induced anemia (CIA) but associated with serious adverse events. Safer alternatives would be beneficial in this population. The efficacy and safety of ferric carboxymaltose (FCM)